Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 11(1): 22593, 2021 11 19.
Article in English | MEDLINE | ID: mdl-34799645

ABSTRACT

Mesenchymal progenitors differentiate into several tissues including bone, cartilage, and adipose. Targeting these cells in vivo is challenging, making mesenchymal progenitor cell lines valuable tools to study tissue development. Mesenchymal stem cells (MSCs) can be isolated from humans and animals; however, obtaining homogenous, responsive cells in a reproducible fashion is challenging. As such, we developed two mesenchymal progenitor cell (MPC) lines, MPC1 and MPC2, generated from bone marrow of male C57BL/6 mice. These cells were immortalized using the temperature sensitive large T-antigen, allowing for thermal control of proliferation and differentiation. Both MPC1 and MPC2 cells are capable of osteogenic, adipogenic, and chondrogenic differentiation. Under osteogenic conditions, both lines formed mineralized nodules, and stained for alizarin red and alkaline phosphatase, while expressing osteogenic genes including Sost, Fgf23, and Dmp1. Sost and Dmp1 mRNA levels were drastically reduced with addition of parathyroid hormone, thus recapitulating in vivo responses. MPC cells secreted intact (iFGF23) and C-terminal (cFGF23) forms of the endocrine hormone FGF23, which was upregulated by 1,25 dihydroxy vitamin D (1,25D). Both lines also rapidly entered the adipogenic lineage, expressing adipose markers after 4 days in adipogenic media. MPC cells were also capable of chondrogenic differentiation, displaying increased expression of cartilaginous genes including aggrecan, Sox9, and Comp. With the ability to differentiate into multiple mesenchymal lineages and mimic in vivo responses of key regulatory genes/proteins, MPC cells are a valuable model to study factors that regulate mesenchymal lineage allocation as well as the mechanisms that dictate transcription, protein modification, and secretion of these factors.


Subject(s)
Adipocytes/cytology , Cell Culture Techniques , Chondrocytes/cytology , Mesenchymal Stem Cells/cytology , Osteocytes/cytology , Animals , Cell Differentiation , Cell Line , Cell Lineage , Cell Proliferation , Fibroblast Growth Factor-23/metabolism , Immunophenotyping , Male , Mice , Mice, Inbred C57BL , RNA, Messenger/metabolism
2.
Nutrients ; 11(12)2019 Dec 16.
Article in English | MEDLINE | ID: mdl-31888255

ABSTRACT

Polyphenols are widely acknowledged for their health benefits, especially for the prevention of inflammatory and age-related diseases. We previously demonstrated that hydroxytyrosol (HT) and procyanidins (PCy), alone or in combination, drive preventive anti-osteoathritic effects in vivo. However, the lack of sufficient clinical evidences on the relationship between dietary phytochemicals and osteoarthritis remains. In this light, we investigated in humans the potential osteoarticular benefit of a grapeseed and olive extract (OPCO) characterized for its hydroxytyrosol (HT) and procyanidins (PCy) content. We first validated, in vitro, the anti-inflammatory and chondroprotective properties of the extract on primary cultured human articular chondrocytes stimulated by interleukin-1 beta (IL-1 ß). The sparing effect involved a molecular mechanism dependent on the nuclear transcription factor-kappa B (NF-κB) pathway. To confirm the clinical relevance of such a nutritional strategy, we designed an innovative clinical approach taking into account the metabolites that are formed during the digestion process and that appear in circulation after the ingestion of the OPCO extract. Blood samples from volunteers were collected following ingestion, absorption, and metabolization of the extract and then were processed and applied on human primary chondrocyte cultures. This original ex vivo methodology confirmed at a clinical level the chondroprotective properties previously observed in vitro and in vivo.


Subject(s)
Absorption, Physicochemical/drug effects , Anti-Inflammatory Agents/pharmacology , Chondrocytes/drug effects , Grape Seed Extract/pharmacology , Plant Extracts/pharmacology , Polyphenols/pharmacology , Adult , Cells, Cultured , Healthy Volunteers , Humans , Interleukin-1beta/blood , Male , NF-kappa B/blood , Phenylethyl Alcohol/analogs & derivatives , Phenylethyl Alcohol/pharmacology , Proanthocyanidins/pharmacology , Young Adult
3.
J Bone Miner Res ; 33(5): 930-944, 2018 05.
Article in English | MEDLINE | ID: mdl-29314250

ABSTRACT

Approximately 10% of all bone fractures do not heal, resulting in patient morbidity and healthcare costs. However, no pharmacological treatments are currently available to promote efficient bone healing. Inhibition of Ca2+ /calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) reverses age-associated loss of trabecular and cortical bone volume and strength in mice. In the current study, we investigated the role of CaMKK2 in bone fracture healing and show that its pharmacological inhibition using STO-609 accelerates early cellular and molecular events associated with endochondral ossification, resulting in a more rapid and efficient healing of the fracture. Within 7 days postfracture, treatment with STO-609 resulted in enhanced Indian hedgehog signaling, paired-related homeobox (PRX1)-positive mesenchymal stem cell (MSC) recruitment, and chondrocyte differentiation and hypertrophy, along with elevated expression of osterix, vascular endothelial growth factor, and type 1 collagen at the fracture callus. Early deposition of primary bone by osteoblasts resulted in STO-609-treated mice possessing significantly higher callus bone volume by 14 days following fracture. Subsequent rapid maturation of the bone matrix bestowed fractured bones in STO-609-treated animals with significantly higher torsional strength and stiffness by 28 days postinjury, indicating accelerated healing of the fracture. Previous studies indicate that fixed and closed femoral fractures in the mice take 35 days to fully heal without treatment. Therefore, our data suggest that STO-609 potentiates a 20% acceleration of the bone healing process. Moreover, inhibiting CaMKK2 also imparted higher mechanical strength and stiffness at the contralateral cortical bone within 4 weeks of treatment. Taken together, the data presented here underscore the therapeutic potential of targeting CaMKK2 to promote efficacious and rapid healing of bone fractures and as a mechanism to strengthen normal bones. © 2018 American Society for Bone and Mineral Research.


Subject(s)
Bony Callus/enzymology , Calcium-Calmodulin-Dependent Protein Kinase Kinase/metabolism , Fracture Healing/physiology , Hedgehog Proteins/metabolism , Osteogenesis/physiology , Signal Transduction/physiology , Animals , Benzimidazoles/pharmacology , Collagen Type I/metabolism , Fracture Healing/drug effects , Male , Mice , Naphthalimides/pharmacology , Osteogenesis/drug effects
4.
Sci Rep ; 6: 33527, 2016 09 19.
Article in English | MEDLINE | ID: mdl-27640363

ABSTRACT

Polyphenols exert a large range of beneficial effects in the prevention of age-related diseases. We sought to determine whether an extract of olive and grape seed standardized according to hydroxytyrosol (HT) and procyanidins (PCy) content, exerts preventive anti-osteoathritic effects. To this aim, we evaluated whether the HT/PCy mix could (i) have in vitro anti-inflammatory and chondroprotective actions, (ii) exert anti-osteoarthritis effects in two post-traumatic animal models and (iii) retain its bioactivity after oral administration. Anti-inflammatory and chondroprotective actions of HT/PCy were tested on primary cultured rabbit chondrocytes stimulated by interleukin-1 beta (IL-1ß). The results showed that HT/PCy exerts anti-inflammatory and chondroprotective actions in vitro. The preventive effect of HT/PCy association was assessed in two animal models of post-traumatic OA in mice and rabbits. Diet supplementation with HT/PCy significantly decreased the severity of post-traumatic osteoarthritis in two complementary mice and rabbit models. The bioavailability and bioactivity was evaluated following gavage with HT/PCy in rabbits. Regular metabolites from HT/PCy extract were found in sera from rabbits following oral intake. Finally, sera from rabbits force-fed with HT/PCy conserved anti-IL-1ß effect, suggesting the bioactivity of this extract. To conclude, HT/PCy extract may be of clinical significance for the preventive treatment of osteoarthritis.


Subject(s)
Grape Seed Extract/administration & dosage , Grape Seed Extract/therapeutic use , Interleukin-1beta/metabolism , Olea/chemistry , Osteoarthritis/drug therapy , Osteoarthritis/prevention & control , Wounds and Injuries/complications , Administration, Oral , Animals , Anterior Cruciate Ligament/drug effects , Anterior Cruciate Ligament/surgery , Biflavonoids/pharmacology , Biflavonoids/therapeutic use , Catechin/pharmacology , Catechin/therapeutic use , Cyclooxygenase 2/metabolism , Diet , Dinoprostone/metabolism , Disease Models, Animal , Female , Grape Seed Extract/pharmacology , Male , Mass Spectrometry , Matrix Metalloproteinase 13/genetics , Matrix Metalloproteinase 13/metabolism , Metabolome , Mice, Inbred C57BL , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/metabolism , Osteoarthritis/blood , Osteoarthritis/etiology , Phenylethyl Alcohol/analogs & derivatives , Phenylethyl Alcohol/pharmacology , Phenylethyl Alcohol/therapeutic use , Proanthocyanidins/pharmacology , Proanthocyanidins/therapeutic use , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rabbits
5.
Drug Discov Today ; 19(10): 1649-58, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24955836

ABSTRACT

Osteoarthritis (OA) is a degenerative joint disease with no curative treatments. Many studies have begun to demonstrate the efficacy of nutraceuticals for slowing down OA. Animal models are utilized as a compulsory step in demonstrating the protective potential of these compounds on joint health. Nevertheless, there exist a wide variety of available OA models and selecting a suitable system for evaluating the effects of a specific compound remains difficult. Here, we discuss animal studies that have investigated nutraceutical effects on OA. In particular, we highlight the large spectrum of animal models that are currently accepted for examining the OA-related effects of nutraceuticals, giving recommendations for their use.


Subject(s)
Dietary Supplements , Models, Animal , Osteoarthritis/diet therapy , Animals , Joints , Osteoarthritis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...